Received Feb 17, 2026
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| HPV9 | HPV (GARDASIL 9) | MERCK & CO. INC. | 1 | — | — |
| HPV9 | HPV (GARDASIL 9) | MERCK & CO. INC. | 2 | — | — |
HCP reported a 26-year-old female received an initial dose of GARDASIL 9 in November of 2024 (exact date unknown) and then received their second dose 02/11/2026; No Additional AE; This spontaneous report was received from a nurse practitioner and refers to a 26-year-old female patient. The patient's medical history, concurrent conditions and concomitant therapies were not reported. On an unknown date in November 2024, the patient was vaccinated with the first dose of Human Papillomavirus 9-valent Vaccine, Recombinant (GARDASIL 9) 0.5 mL (route of administration, vaccination site, lot # and expiration date were not reported) administered for prophylaxis. On 11-Feb-2026, the patient was vaccinated with the second dose of Human Papillomavirus 9-valent Vaccine, Recombinant (GARDASIL 9) 0.5 mL (route of administration, vaccination site, lot # and expiration date were not reported) administered for prophylaxis (inappropriate schedule of product administration). No side effects or symptoms were reported. No Additional adverse event (AE) and no product quality complaint (PQC) was noted. Lot # is being requested and will be submitted if received.